Moreover, although a small-molecule inhibitor of USP2 alone can partially suppress the in vivo growth of p53-wild-type mammary tumor xenografts, more strikingly, USP2 inhibition and PD-1/PD-L1 blockade in combination promote vigorous tumor regression and long-term survival of all tumor-bearing mice. Here, CD274 is linked to breast cancer.